$CMPR

Cimpress (NASDAQ:CMPR) Reaches New 52

Cimpress plc (NASDAQ:CMPR) hit a new 52-week high on Tuesday, trading up to $105.00 and last at $104.94 versus a prior close of $102.39. The article also cites recent analyst actions: Zacks downgraded to “hold,” while Truist set a $110 target and Barrington raised its to $113. On April 29, Cimpress reported Q1 EPS of $0.55 and revenue of $886.21M.

Original reporting
Published May 29, 2026, 1:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 2:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cimpress (NASDAQ:CMPR) Reaches New 52 — source image
Decision brief

The 30-second read

$CMPRNeutralMed
01

Why it matters

CMPR’s new 52-week high suggests improving near-term sentiment, while the downgrade-to-hold and insider selling can cap upside and increase two-sided trading around the next earnings/updates.

02

Market read

Best used as a momentum/positioning input for CMPR rather than a standalone fundamental catalyst.

03

What to watch

The article bundles multiple analyst actions without detailing changes in underlying assumptions; traders may over-weight the price print versus fundamentals.

Relevance 8/10Novelty 6/10Timing: During Tuesday’s session after CMPR printed a new 52-week high.

Background

The article summarizes CMPR’s Tuesday trading range, recent analyst rating/target changes, the last reported quarter’s EPS/revenue vs consensus, and an EVP share sale disclosed via SEC filing.

Company-level read

Ticker impact

$CMPRNeutralMedium confidence
Context

Cimpress shares hit a new 52-week high and the article also cites recent analyst rating/target changes plus an insider Form 4 sale.

Expected impact

Choppy upside bias: likely follow-through attempts near resistance, but expect volatility around analyst/insider headlines.

Evidence & confidence

The piece provides a concrete price move (52-week high), multiple rating/target updates, and an executive sale; however it does not introduce a new fundamental catalyst beyond the already-referenced earnings date.

Market effects

Limited read-across; mass customization/web-to-print peers are not specifically mentioned with new guidance.

None stated.

None stated.

Counterpoint

The breakout may be sentiment-driven around analyst target chatter rather than a fresh operating catalyst, so mean reversion risk remains high.

Key entities

  • Cimpress plc

    CMPR stock reached a new 52-week high; article cites analyst rating/target changes and an EVP insider sale.

Related articles

$CMPRLow

CIMPRESS plc (CMPR): Results of Operations and Financial Condition

CIMPRESS plc (CMPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. cmpr-20260729 0001262976 false 0001262976 2024-10-30 2024-10-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date o

$ARMMed

Arm CEO: Chip Supply, Not Demand, Is Now the Real Constraint

Arm Holdings CEO Rene Haas stated on 16 September 2026 that chip manufacturing capacity, not demand, is the industry's primary constraint. He reiterated confidence in meeting a $2bn AGI CPU revenue target, up from previous guidance. Arm's shares rose 3.3% in pre-market trading. Q2 2026 revenue reached $1.29bn, up from $1.05bn a year earlier, with net income more than doubling to $270m.

$BIAFMed

BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant - bioAffinity Technologies (NASDAQ

BioAffinity Technologies (NASDAQ:BIAF) shares rose 50.47% to $8.05 Thursday after receiving a Hong Kong patent for its CyPath Lung diagnostic. The patent complements a 2025 patent in China, covering a region with high lung cancer incidence. CyPath Lung has shown strong clinical performance, with 92% sensitivity and 87% specificity in trials. The company's warrants (NASDAQ:BIAFW) also gained nearly 20%.

$INTCHigh

Intel Stock Jumps As Analysts Boost Targets And AI Bets Grow

Intel (INTC) stock rose 9.43% on strong AI chip demand and data-center growth. Analysts raised price targets, citing AI-driven turnaround and manufacturing progress. Despite negative earnings, cash flow is solid, and partnerships like SK Hynix's potential fab lease add catalysts. INTC's stock has climbed from the $80s to over $110, with analysts setting targets around $120-$145.